行情

CRL

CRL

查尔斯河实验室
NYSE

实时行情|Nasdaq Last Sale

324.66
-7.44
-2.24%
盘后: 325.22 +0.56 +0.17% 16:43 01/21 EST
开盘
334.94
昨收
332.10
最高
335.05
最低
324.03
成交量
38.13万
成交额
--
52周最高
460.21
52周最低
249.48
市值
163.84亿
市盈率(TTM)
42.04
分时
5日
1月
3月
1年
5年
Patton Fund Management, Inc. Buys Arista Networks Inc, Equifax Inc, Ford Motor Co, Sells ...
Investment company Patton Fund Management, Inc. (Current Portfolio) buys Arista Networks Inc, Equifax Inc, Ford Motor Co, Eli Lilly and Co, Pfizer Inc, sells iShares Core S&P 500 ETF, Rockwell Automation Inc, Danaher Corp, Align Technology Inc, Charles Riv...
GuruFocus.com · 1天前
PFG Advisors Buys Pacer Lunt Large Cap Alternator ETF, First Trust NASDAQ Rising Dividend ...
Investment company PFG Advisors (Current Portfolio) buys Pacer Lunt Large Cap Alternator ETF, First Trust NASDAQ Rising Dividend Achievers ETF, Pacer US Small Cap Cash Cows 100 ETF, Amplify CPW Enhanced Dividend Income ETF, Charles River Laboratories Inter...
GuruFocus.com · 2天前
New Potomac Partners, LLC Buys Simon Property Group Inc, Invesco BulletShares 2027 Corporate ...
Investment company New Potomac Partners, LLC (Current Portfolio) buys Simon Property Group Inc, Invesco BulletShares 2027 Corporate Bond ETF, sells Invesco BulletShares 2021 Corporate Bond ETF, AT&T Inc, Invesco BulletShares 2022 Corporate Bond ETF, Duke E...
GuruFocus.com · 2天前
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
WILMINGTON, Mass., January 20, 2022--Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
Business Wire · 3天前
3 Reasons Why Charles River (CRL) Is a Great Growth Stock
Charles River (CRL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks · 4天前
Charles River and Valo Health partner to provide AI-Enabled drug discovery solutions
Charles River Laboratories International (CRL) and Valo Health announces the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with company’s drug discovery and development capabilities
Seekingalpha · 4天前
Charles River, Valo Health Announce Strategic Partnership To Provide Clients With Access To AI-Enabled Drug Discovery Solutions
Charles River Laboratories International, Inc. (NYSE:CRL) and Valo Health, LLC ("Valo"), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the
Benzinga · 4天前
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions
WILMINGTON, Mass. & BOSTON, January 19, 2022--Charles River and Valo Health announce a multiyear strategic partnership to provide clients with access to AI-enabled drug discovery.
Business Wire · 4天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CRL最新的财务预测,通过CRL每股收益,每股净资产,每股现金流等数据分析查尔斯河实验室近期的经营情况,然后做出明智的投资选择。
分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

35.71%强力推荐
50.00%买入
14.29%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CRL价格均价为443.73,最高价位465.00,最低价为400.00。
最高465.00
均价443.73
最低400.00
现价324.66
EPS
实际EPS
预期EPS
0.681.352.022.70
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 818
机构持股: 5,172.77万
持股比例: 102.50%
总股本: 5,046.44万
类型机构数股数
增持
231
219.58万
建仓
79
99.11万
减持
254
357.61万
平仓
36
31.14万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chairman/President/Chief Executive Officer/Director
James Foster
Chief Financial Officer/Executive Vice President
David Smith
Chief Operating Officer/Executive Vice President
Birgit Girshick
Executive Vice President
William Barbo
Executive Vice President
Joseph LaPlume
Lead Director/Independent Director
George Milne
Independent Director
Nancy Andrews
Independent Director
Robert Bertolini
Independent Director
Deborah Kochevar
Independent Director
George Llado
Independent Director
Martin Mackay
Independent Director
George Massaro
Independent Director
Richard Reese
Independent Director
Richard Wallman
Independent Director
Virginia Wilson
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
CRL 简况
Charles River Laboratories International, Inc.是一家提供全方位服务的早期合同研究公司。该公司为帮助制药和生物技术公司、政府机构和学术机构进行研究和药物开发而提供产品和服务。该公司通过两个部门运营:探索及安全评估部门和制造解决方案(制造)部门。探索及安全评估部门包括通过早期开发过程获取药物所需的服务,包括探索服务(一种非监管服务,可帮助客户识别、筛选和选择用于药物开发的先导化合物)以及受监管和不受监管的(良好实验室规范(GLP)和非GLP)安全评估服务。制造部门包括微生物解决方案、生物制剂解决方案和禽疫苗服务。

微牛提供Charles River Laboratories Intl. Inc(NYSE-CRL)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRL股票基本功能。